Consequently, in the year 2000, a substantial success was achieved in the development of ADC with the advent of the anti-CD33-targeted agent gemtuzumab ozogamicin for adults with acute myeloid leukemia [5]. This evidence concerns the gene CD33 and acute myeloid leukemia.